Sonia de Kondserovsky

Life Sciences transactions

Sonia de Kondserovsky has been the lead lawyer with respect to the following transactions:

• Advising the Pierre Fabre Group on a number of transactions, including the acquisition of Swiss biotech Verticalbio, the sale of its CDMO business to Fareva, and its strategic collaboration with Foresee for the R&D and industrial development of oncology products for pre-filled syringes.
• Advising UMPC (US) in connection with its participation in various rounds of financing for the French biotech Gensight.
• Advising Eurazeo (Nov Santé) on its acquisition of a stake in Oncodesign.
• Advising the medical devices group Stryker on its acquisition of Serf.
• Advising Japan-based global pharmaceutical group Santen Pharmaceutical Co., Ltd. on several transactions, including on its purchase of rights for ophthalmic drugs in Japan, Asia/Pacific and Europe from Merck & Co. for USD600 million and on its public tender offer on Novagali (Euronext C) and subsequent squeeze out.
• Advising Sanofi in connection with its collaboration and licensing agreement with the Japanese laboratory Kyowa Hakko Kirin.
• Advising Becton Dickinson on its French corporate restructuring in the context of the transfer of its respiratory solutions business to Vyaire Medical, a newly created joint venture.
• Advising Nordic Pharma in connection with its collaboration and licensing agreement with Nippon Kayaku, granting Nordic Pharma exclusive rights to develop and market Spanidin® (gusperimus) outside Japan.
• Advising Innothéra on its strategic partnership with BioSerenity for the research and industrial development of connected medical devices.
• Advising Sanofi on a number of transactions, including the sale of its Quétigny manufacturing site to Delpharm, the sale of its Trandolapril manufacturing and marketing rights to Abbott, the spin-off of its R&D activities in bone diseases (Proskelia) and anti-infectives (Novexel), followed by equity investments by PE funds (Warburg, Atlas, Sofinnova).
• Advising Terumo Corporation on its acquisition of Bolton Medical SAS.
• Advising Emergent Biotechnologies on its acquisition of a joint venture interest and product portfolio from Sanofi.
  

Other transactions      

• Advising Société Générale on more than a dozen of transactions, including its acquisitions of several fintech companies (Shine and Treezor), its acquisitions through ALD in Spain (BanSabadell Renting and Reflex de Alquiler), in the Netherlands (SternLease BV) and its joint ventures with Mitsubishi in Thailand and Malaysia.
• Advising Renault on its program to divest its automotive distribution business in 7 jurisdictions (Sweden, Denmark, Hungary, Serbia, Bulgaria, Slovenia and Croatia).
• Advising Proparco on its acquisition of a stake in Finafrica.
• Advising Société Générale on its participation in a Cap Gemini/Credit Agricole joint-venture named “Azqore”.
• Advising BIC on its acquisition of Advanced Magnetic Interaction.
• Advising Sodexo in connection with the sale of its global homecare division to Halifax group.
• Advising of the insurance group AON on numerous acquisitions in France, including the acquisition of Apollo Conseil & Courtage, Chapka Assurances and Ovatio.
• Advising Coca-Cola on its acquisition of Tropico.
• Advising Alcatel-Lucent on a number of transactions, including the sale of its cyber security and eavesdropping business to Thales, the sale of its global RFS business to Alcatel Shanghai Bell (China), the sale of its global Adixen business to Pfeiffer (€200 million), the sale of its global Dunerkermotoren business to Triton (€145 million) and its acquisition of Velocix.
• Advising Allianz on the transnational intra-group merger of its French subsidiary with the German parent company.

Individual Recognitions

• Chambers France – Pharma/Life Sciences : Corporate – Band 3 – 2025

“She is attentive, reliable and has good expertise in the field of M&A and pharma. She is also very tenacious in negotiations, and she is innovative and creative.”

“Sonia is reactive, competent and has a very good international network.”

“She is available, her presence is very helpful on complex cases, she is able to find solutions, and she knows the pharma sector very well.”

• Best Lawyers – Biotechnology and Life Sciences Practice; Corporate Law ; Mergers and acquisition Law – 2020-2026
• Sonia is regularly recommended in the healthcare sector by legal directories LMG, Legal 500, and PLC Which Lawyer.

Team Recognitions

• Chambers France – Pharma/Life Sciences – Band 4 – 2025

“The team have deep knowledge of our industry and a strong track record.”

“I like the firm's knowledge of the market and our company, their availability and their responsiveness.”

“The firm answers my needs in terms of cross-practice skills, values and empathy. The lawyers listen to the clients and they are available.”

“I am satisfied with their interpersonal skills with the client and their ability to be a real business partner.”

• Legal 500 - Industry Focus: Healthcare and Life Sciences - Tier 2 – 2025

“Sonia de Kondserovsky is an extremely serious lawyer who always gives the best possible advice to her clients. It is a privilege to be able to work with her.”

“Sonia de Kondserovsky is the partner in charge of the healthcare team. She has extensive experience in this field and is heavily involved in strategy and implementation, from negotiation to review of written documentation by experienced colleagues.”

“International firm with extensive expertise. Interest in complex cases requiring varied and highly specialised resources and expertise.”

“Skills in the health sector and diversity in areas of expertise (litigation, administrative, regulatory).”

“The team is very cohesive and diligent in implementation. It is very experienced in acquisitions, divestments and industrial contracts in the field of pharmaceuticals and medical devices. It has good international experience and benefits from a competent network in the field, particularly in the US.”

• Legal 500 - Private Equity: LBO - Tier 3 – 2025

Availability, in-depth expertise, ability to support both SMEs and large international groups.”

• Legal 500 - Mergers & acquisitions - Tier 4 – 2025

"Great organisational capabilities combined with a focused professional approach and excellent connections worldwide.”

Legal doctrine

• "The reform of French Contract law and its impact on mergers and acquisitions", Revue de Droit Bancaire et Financier - Revue Bimestrielle Lexis Nexis/Jurisclasseur.
• "The Reform of French Contract Law in an M&A context: revolution or status quo?", Journal of International Banking and Finance law.
• "International and Transnational Mergers", Actes Pratiques (co-authored with Professor Michel Menjucq, comparative study between the regime under transposed European law and the regime under private international law).
• "Contributions under the spin off regime", Jurisclasseur Commercial (booklet containing a comparative study between contributions under the spin-off regime and contributions in kind).